A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2001 participants.

Also called NCT07794579

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,001 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07794579
  • EU CT 2026-526175-35-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, China, Czechia, Germany, India, Japan, Mexico, Puerto Rico, South Korea, Spain, Taiwan (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07794579. Randomized; double masking; primary purpose treatment. Start 2026-08-26 (actual); primary completion 2029-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Acronym
ATTAIN-NOW
Condition
Overweight
Condition
Prediabetic State
Condition
Prehypertension
Condition
Obesity, Abdominal
Intervention (Drug)
Orforglipron
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct07794579
Content hash
95e536c9379a13cb9ded547b1fc4f1cfbcb4aeb9c2358f448194c63a42cb78d8